PTC Therapeutics PTCT Translarna — Sales Allowance And Other Related Costs

Similar metrics at other companies

EXELDiscounts and allowances — Total revenues

-$240.38M-15.3%

MDGLRebates, Co-Pay Assistance, Returns, and Other — Provision related to sales in the current year

$128.95M—

MIRMLivmarli — Product sales, net

$113.8M+55.4%

MDGLChargebacks, Discounts for Prompt Pay and Other Allowances — Provision related to sales in the current year

$37.82M+622%

ALKSOther — Accrued Sales Discounts Allowances And Reserves

$39.62M+97.3%

BYDProduct And Service Other — Promotional Allowance

$2.14M+18.5%

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept ptct:SalesAllowanceAndOtherRelatedCosts.

The official record: PTC Therapeutics’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's translarna — sales allowance and other related costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's translarna — sales allowance and other related costs?: PTC Therapeutics (PTCT) reported translarna — sales allowance and other related costs of $98.6M in Q4 2025.
What does translarna — sales allowance and other related costs mean?: This metric quantifies the deductions taken from gross product sales, including provisions for rebates, chargebacks, distribution fees, and product returns. It serves as a measure of the pricing pressure and commercial friction associated with bringing the therapeutic to market. Monitoring this helps investors understand the net realization rate of the product's gross revenue.